אלופיסל - Alofisel
ש××× ×× !
×ת×ר××: 20/03/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 20/03/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L04AX Other immunosuppressants | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | PERILESIONAL USE | ||||||||||||||||||
| צ×רת ××× ×× | DISPERSION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohnâs disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used only after conditioning of the fistulas. | ||||||||||||||||||
| |||||||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | ||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||
| ת×פע×ת ××××× | Undesirable effects | ||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
Â
 | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×××פ××¡× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | TIGENIX, S.A.U. |
| ×©× ××¢× ×ר×ש×× | TAKEDA ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 1/2018. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 20/03/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־16 בספטמבר 2025 ב־16:57